Clinomics Europe has joined the European Liquid Biopsy Society (ELBS)
We are thrilled to announce that Clinomics Europe has joined the European Liquid Biopsy Society (ELBS)! As one of over 70 partners from academia and industry, Clinomics Europe is now part of a dynamic network working towards the common goal of bringing liquid biopsy tests into clinical routine.
The ELBS network covers all relevant areas needed to achieve this goal, including harmonization of technologies, clinical study design, and interaction with regulatory bodies. By combining the collective expertise and knowledge of its members with the strategic implementation of joint projects, the ELBS is uniquely positioned to drive progress in the field of liquid biopsy.
We are excited to be part of this impressive network, and look forward to working alongside other ELBS members to advance this promising field!
Recent blogs
New developments in the field of circulating tumor cells (2024)
The blog post focuses on how researchers can produce more meaningful, applicable results that directly benefit human health.
Singlera technologies 5: Panseer – detecting pan-cancer signatures years before conventional diagnosis
In the last blog of the year and the concluding chapter of the Singlera series, we are going to explore PanSeer, a blood-based screening test utilizing unique methylation signatures.
Singlera Technologies 4: Catching Pancreatic Cancer early with intricate methylation markers
Enter PDACatch, a novel assay developed to detect circulating tumor DNA methylation signatures with greater sensitivity and accuracy.